Galderma Unveils Innovations in Aesthetic Medicine at AMWC Dubai 2025
ZUG, Switzerland, September 24, 2025 — As Galderma gears up for the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, exciting developments and findings in aesthetic medicine will take center stage. From groundbreaking treatment techniques to innovative products, the company is poised to reveal its latest advancements aimed at meeting the evolving needs of both patients and practitioners.
Highlighting The Shayping Technique™
One of the standout presentations at the conference will focus on the ARTIST post-marketing study. This study showcases The Shayping Technique™, a holistic approach to facial aesthetics utilizing three Restylane® injectables. This technique aims to enhance facial features while catering to diverse patient needs, emphasizing a natural look. The study’s findings suggest that this tailored approach significantly boosts both facial aesthetics and overall appearance, reaffirming the role of personalized treatments in modern aesthetic practices.
Expanding Versatility in Aesthetic Solutions
In addition to highlighting The Shayping Technique™, Galderma’s presentations will delve into the versatility of its aesthetic portfolio. This includes addressing the cosmetic changes that may arise after medication-driven weight loss, along with groundbreaking advancements in regenerative aesthetics and neuromodulation. As patients increasingly seek solutions that accommodate their unique journeys—like recovering volume loss due to weight management—Galderma’s innovative approaches are timely and essential.
A Comprehensive Symposium and Expert Sessions
Galderma will also showcase its leadership through a comprehensive program of events at its booth (B-145). Attendees can look forward to a series of educational sessions, including a symposium dedicated to the aesthetic changes resulting from medication-induced weight loss. This symposium will feature prominent aesthetic experts who will explore effective treatment algorithms and conduct live demonstrations, further solidifying Galderma’s commitment to ongoing education for practitioners.
Insights from Groundbreaking Studies
Among the latest updates is significant data focusing on Restylane hyaluronic acid (HA) injectables, uniquely formulated to work harmoniously with the body’s natural HA for results that feel authentic. The presentation of data supporting the safety and efficacy of Restylane Shaype™, enhanced by new NASHA HD™ technology, will highlight its effectiveness used alone or in combination with other Restylane products. The study found that 100% of participants reported improvements in chin definition and aesthetics at both four and eight weeks post-injection.
Moreover, this year’s symposium will provide insights into the critical balance between enzyme volume and filler volume, essential for achieving predictable filler dissolution outcomes. This knowledge represents a substantial leap toward refining practices in injectable aesthetics and patient satisfaction.
Regenerative Aesthetics: Sculptra® Focus
In a proactive approach to regenerative aesthetics, Galderma will share results from a recent consensus on Sculptra®, the first regenerative biostimulator. The data will illustrate its capability to stimulate fibroblast activity across different skin layers, helping to restore skin quality and firmness while reducing the visible signs of aging. This information is pivotal for practitioners adapting to changes in patient needs, particularly those recovering from significant weight loss.
The symposium will include a session on the synergistic effects of combining Sculptra with other products like Restylane Lyft® or Contour™. This combination is particularly effective in enhancing skin quality and appearance in patients experiencing facial volume loss from medication-driven weight management.
Innovations in Liquid Neuromodulation
Galderma will also unveil findings from studies concerning Relfydess™ (RelabotulinumtoxinA), the first ready-to-use liquid neuromodulator developed with PEARL™ Technology. This innovative product streamlines the clinical workflow, ensuring consistent dosing without the need for reconstitution. Research indicates promising outcomes, with rapid onset of effects and high satisfaction rates from subjects, suggesting a shift in patient expectations toward neuromodulation treatments.
Commitment to Education and Collaboration
Flemming Ørnskov, M.D., MPH, and CEO of Galderma, expressed the importance of engaging directly with the medical aesthetics community. “Our presence at AMWC Dubai reflects Galderma’s commitment to being a true partner to the medical aesthetics community,” he stated. This underscores their ongoing dedication to innovation and responsiveness to practitioner and patient needs.
Exploring the Broader Landscape of Aesthetics
Galderma’s presence at AMWC signals a significant contribution to the discourse around the future of aesthetic medicine. By presenting the latest in clinical data, collaborative sessions, and new product innovations, they are not only setting a standard for industry practices but also addressing pressing patient concerns and evolving aesthetic preferences.
About Galderma
Founded in 1981 and headquartered in Zug, Switzerland, Galderma has established itself as a leader in dermatology, with a global reach across approximately 90 countries. The company’s focus on science-backed innovations within Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology positions it to meet diverse consumer needs, ultimately enhancing the quality of life for countless individuals.
For more information about Galderma’s activities at AMWC and to explore the advancements they are showcasing, visit their official website.
Stay Informed
As the aesthetic landscape evolves, keeping abreast of new findings and innovations is crucial. The insights from Galderma presented at AMWC will not only enrich professional practices but also empower patients to achieve their aesthetic goals more effectively.
